HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dubois, C. L. Search for Related Content PubMed PubMed Citation Articles by Dubois, C. L.

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab

Christophe L. Dubois, MD^*, Ann Belmans, MSc^*, Christopher B. Granger, MD, FACC, Paul W. Armstrong, MD, FACC, Lars Wallentin, MD, FACC^||, Paolo M. Fioretti, MD, FACC^¶, José L. López-Sendón, MD, FACC^#, Freek W. Verheugt, MD, FACC^**, Jürgen Meyer, MD, FACC, Frans Van de Werf, MD, FACC^*,* ASSENT-3 Investigators

^* Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
Department of Public Health, Biostatistical Centre, Catholic University Leuven, Leuven, Belgium
Duke Clinical Research Institute, Durham, North Carolina, USA
Department of Cardiology, University of Alberta, Edmonton, Canada
^|| Department of Cardiology, University of Uppsala, Uppsala, Sweden
^¶ Department of Cardiology, Istituto di Cardiologia, Udine, Italy
^# Department of Cardiology, Hospital Gregorio Marañon, Madrid, Spain
^** Department of Cardiology, University Medical Center Nijmegen, Nijmegen, The Netherlands
Department of Cardiology, Johannes Gutenberg-University, Mainz, Germany

View larger version (28K): [in a new window]   Figure 1 Clinical end points and pairwise treatment comparisons for outcome after elective PCI based on hazard ratios. In addition, 95% confidence intervals (CI) and p values are presented. ABC = abciximab; ENOX = enoxaparin; UFH = unfractionated heparin. Composite efficacy end point = 30-day mortality, in-hospital myocardial infarction, or in-hospital refractory ischemia. Squares = ENOX versus UFH; triangles = ABC versus UFH.

View larger version (30K): [in a new window]   Figure 2 Clinical end points and pairwise treatment comparisons for outcome after urgent PCI based on hazard ratios. In addition, 95% confidence intervals (CI) and p values are presented. ABC = abciximab; ENOX = enoxaparin; UFH = unfractionated heparin. Composite efficacy end point = 30-day mortality, in-hospital myocardial infarction, or in-hospital refractory ischemia. Squares = ENOX versus UFH; triangles = ABC versus UFH.

View larger version (30K): [in a new window]   Figure 3 Clinical end points and pairwise treatment comparisons for outcome after early PCI based on hazard ratios. In addition, 95% confidence intervals (CI) and p values are presented. ABC = abciximab; ENOX = enoxaparin; UFH = unfractionated heparin. Composite efficacy end point = 30-day mortality, in-hospital myocardial infarction, or in-hospital refractory ischemia. Squares = ENOX versus UFH; triangles = ABC versus UFH.